MRTX News Alert Mirati Therapeutics Inc (MRTX) 15.67 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mirati Therapeutics Inc (MRTX) 15.67 $MRTX

Mirati Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 19, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 10:00 a.m. Eastern Time in New York.
MRTX: 15.67 (+0.30)

Mirati beats 3Q profit forecasts
Automated Insights - Mon Nov 10, 7:31AM CST
SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Monday reported a third-quarter loss of $8.6 million.
MRTX: 15.67 (+0.30)

Mirati Therapeutics beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:27AM CST

MRTX: 15.67 (+0.30)

Mirati Therapeutics Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Mon Nov 10, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2014 and provided an update on its drug development programs.
MRTX: 15.67 (+0.30)

Michael Grey Joins Mirati Therapeutics Board of Directors
PR Newswire - Thu Nov 06, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of directors.
MRTX: 15.67 (+0.30)

Mirati Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
PR Newswire - Wed Sep 10, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 10:30 a.m. Eastern Time in New York.
MRTX: 15.67 (+0.30)

Mirati Therapeutics Initiates Phase 1 Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
PR Newswire - Thu Sep 04, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in its Phase 1 clinical study of MGCD516 in the treatment of patients with advanced solid tumors, with an initial focus on non-small cell lung cancer (NSCLC). MGCD516 is a Receptor Tyrosine Kinase (RTK) inhibitor with molecular targets that act as critical genetic drivers of cancer progression.
MRTX: 15.67 (+0.30)

Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma
PR Newswire - Mon Aug 11, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome (MDS). Orphan drug designation is also being sought for bladder cancer patients with specific genetic alterations.
MRTX: 15.67 (+0.30)

Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Fri Aug 08, 7:00AM CDT
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX) today reported financial results for the second quarter ended June 30, 2014 and provided an update on its drug development programs.
MRTX: 15.67 (+0.30)

Mirati Therapeutics Added to Russell 2000 Index
PR Newswire - Mon Jun 30, 3:01PM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company has been added to the Russell 2000® Index following the annual reconstitution of its U.S. and global equity indexes on June 27, 2014.
MRTX: 15.67 (+0.30)

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome
PR Newswire - Tue Jun 17, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration as a treatment for myelodysplastic syndrome (MDS). Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as a treatment for intermediate and high-risk MDS, as well as a single agent treatment in patients with diffuse large B-cell lymphoma (DLBCL) and bladder cancer targeting specific genetic mutations in histone acetylation that increase the likelihood of response in tumor cells.
MRTX: 15.67 (+0.30)

Mirati Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference
PR Newswire - Thu Jun 12, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 9:00 a.m. Eastern Time in New York.
MRTX: 15.67 (+0.30)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 165

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 58

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 153

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 148

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 247

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 89

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading

Top 5 Most Recently Viewed Articles

Verizon Secures $66 Million EIS Partnership with Coast Guard

Updated Category News Views 283

Verizon Awarded $66 Million Enterprise Infrastructure Solutions Contract In a significant development, Verizon Business has been awarded a substantial contract valued at up to $66 million by the U.S. Coast Guard. This eight-year Enterprise Infrastructure Solutions (EIS) task order represents a robust commitment to enhancing the Coast Guard's communication and operational...

Continue Reading
Icelandic Glacial Becomes Laver Cup 2025's Official Water

Updated Category News Views 168

Icelandic Glacial to Hydrate Laver Cup 2025 Attendees Icelandic Glacial™, recognized for its exceptional quality and purity, has been designated as the Official Water for the highly anticipated Laver Cup 2025. This prestigious tournament is scheduled to take place at the Chase Center, showcasing top-tier men's tennis. A Perfect Fit for a Grand Event Coming from the...

Continue Reading
Dick's Sporting Goods Shows Promise for Q3 Amid Market Trends

Updated Category News Views 196

Dick's Sporting Goods Anticipates Strong Q3 Results Dick's Sporting Goods Inc. (NYSE: DKS) is gearing up for its fiscal third-quarter earnings report, creating buzz among investors eager to understand how the retailer is managing consumer demand and its recent strategic moves. As the company prepares to disclose its earnings, the market remains cautiously optimistic,...

Continue Reading
HyOrc Corporation Charts New Path with Green Fuel Innovations

Updated Category News Views 165

HyOrc Corporation's Strategic Market Transformation HyOrc Corporation (OTCID: HYOR) is making significant strides in the clean energy sector with a recent change in its trading symbol on the OTC markets. This evolution reflects not only a fresh identity but also the dynamic advancements the company is achieving in green fuel technologies and hydrogen mobility....

Continue Reading
Exploring Nature Through Art: BlackBook's New Exhibition

Updated Category News Views 227

BlackBook Presents Unveils a Unique Art Exhibition BlackBook Presents is set to embark on an exciting journey with its upcoming art exhibition titled Mother Nature in the Bardo. This innovative presentation, in collaboration with UNESCO's GEM Report, aims to foster meaningful discussions about art, culture, and their profound connection to environmental issues. Through an...

Continue Reading